Rotavirus disease course among immunocompromised patients; 5-year observations from a tertiary care medical centre

Bruijning-Verhagen, Patricia; Nipshagen, Martine D.; Bonten, Marc J. M.

doi:10.1016/j.jinf.2017.08.006

Cited by 10 publications

(7 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In terms of rotavirus, no study has analyzed the risks and severity of rotavirus infection between patients with IBD and healthy individuals. However, a case–control study of 4584 patients with rotavirus infection showed that immunocompromised patients had a 7.4-fold higher risk of hospitalization than the general population [ 19 ]. …”

Section: Vaccine-preventable Diseasesmentioning

confidence: 99%

Expert consensus on vaccination in patients with inflammatory bowel disease in Japan

et al. 2023

View full text Add to dashboard Cite

Immunosuppressive therapies can affect the immune response to or safety of vaccination in patients with inflammatory bowel disease (IBD). The appropriateness of vaccination should be assessed prior to the initiation of IBD treatment because patients with IBD frequently undergo continuous treatment with immunosuppressive drugs. This consensus was developed to support the decision-making process regarding appropriate vaccination for pediatric and adult patients with IBD and physicians by providing critical information according to the published literature and expert consensus about vaccine-preventable diseases (VPDs) [excluding cervical cancer and coronavirus disease 2019 (COVID-19)] in Japan. This consensus includes 19 important clinical questions (CQs) on the following 4 topics: VPDs (6 CQs), live attenuated vaccines (2 CQs), inactivated vaccines (6 CQs), and vaccination for pregnancy, childbirth, and breastfeeding (5 CQs). These topics and CQs were selected under unified consensus by the members of a committee on intractable diseases with support by a Health and Labour Sciences Research Grant. Physicians should provide necessary information on VPDs to their patients with IBD and carefully manage these patients’ IBD if various risk factors for the development or worsening of VPDs are present. This consensus will facilitate informed and shared decision-making in daily IBD clinical practice.

show abstract

Section: Vaccine-preventable Diseasesmentioning

confidence: 99%

Expert consensus on vaccination in patients with inflammatory bowel disease in Japan

et al. 2023

View full text Add to dashboard Cite

show abstract

“…It is known that RV infection may complicate the course of patients with previous conditions especially immunocompromising diseases. 42 This may have an impact on the severity and resource consumption analysis (including antibiotic use). While we cannot exclude the possibility of nosocomial transmission complicating the course of disease and resulting in cost overestimation due to RVGE, we have tried to minimize this bias by only including costs related to the treatment of RVGE in the estimations for nosocomial cases.…”

Section: Discussionmentioning

confidence: 99%

Clinical characteristics, health care resource utilization and direct medical costs of Rotavirus hospitalizations in Spain (2013–2018)

Alfayate-Miguélez

Carazo-Gallego

et al. 2022

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

Rotavirus (RV) is the most common cause of severe gastroenteritis (GE) in infants and young children worldwide and is associated with a significant clinical and economic burden. The objective of this study was to analyze the characteristics, healthcare resource utilization and the direct medical costs related to RVGE hospitalizations in Spain. An observational, multicenter, cross-sectional study was conducted from June 2013 to May 2018 at the pediatric departments of 12 hospitals from different Spanish regions. Children under 5 years of age admitted to the hospital with a confirmed diagnosis of RVGE were selected. Data on clinical characteristics, healthcare resource use and costs were collected from patient records and hospital databases. Most children hospitalized for RVGE did not have any previous medical condition or chronic disease. Forty-seven percent had previously visited the Emergency Room (ER), 27% had visited a primary care pediatrician, and 15% had received pharmacological treatment prior to hospital admission due to an RVGE episode. The average length of a hospital stay for RVGE was 5.6 days, and the mean medical costs of RVGE hospitalizations per episode ranged from 3,940€ to 4,100€. The highest direct medical cost was due to the hospital stay. This study showed a high burden of health resource utilization and costs related to the management of cases of RVGE requiring hospitalization. RV vaccination with high coverage rates should be considered to minimize the clinical and economic impacts of this disease on the health-care system.

show abstract

“…A proportion of episodes in our sample were nosocomial and/or reported having previous medical conditions. It is known that RV infection may complicate the course of patients with previous conditions especially immunocompromising diseases [33]. This may have an impact on the severity and resource consumption analysis (including antibiotic use).…”

Section: Discussionmentioning

confidence: 99%

Clinical Characteristics, Health Care Resource Utilization and Direct Medical Costs of Rotavirus Hospitalizations in Spain (2013-2018)

Arı́stegui

Alfayate-Miguélez

Carazo-Gallego

et al. 2021

Preprint

View full text Add to dashboard Cite

Background: Rotavirus (RV) is the most common cause of severe gastroenteritis (GE) in infants and young children worldwide and is associated with a significant clinical and economic burden. The objective of this study was to analyze the characteristics, healthcare resource utilization and the direct medical costs related to RVGE hospitalizations.Methods: An observational, multicenter, cross-sectional study was conducted from June 2013 to May 2018 at the pediatric departments of 12 hospitals from different Spanish regions. Children under 5 years of age admitted to the hospital with a confirmed diagnosis of RVGE were selected. Data on clinical characteristics, healthcare resource use and costs were collected from patient records and hospital databases.Results: Most children hospitalized for RVGE did not have any previous medical condition or chronic disease. Forty-seven percent had previously visited the ER, 27% had visited a primary care pediatrician, and 15% had received pharmacological treatment prior to hospital admission due to an RVGE episode. The average length of a hospital stay for RVGE was 5.6 days, and the mean medical costs of RVGE hospitalizations per episode ranged from 3,940€ to 4,100€. The highest direct medical cost was due to the hospital stay.Conclusion: This study shows a high burden of health resource utilization and costs related to the management of cases of RVGE requiring hospitalization. RV vaccination with high coverage rates should be considered to minimize the clinical and economic impacts of this disease on the health care system.

show abstract

Rotavirus disease course among immunocompromised patients; 5-year observations from a tertiary care medical centre

Cited by 10 publications

References 27 publications

Expert consensus on vaccination in patients with inflammatory bowel disease in Japan

Expert consensus on vaccination in patients with inflammatory bowel disease in Japan

Clinical characteristics, health care resource utilization and direct medical costs of Rotavirus hospitalizations in Spain (2013–2018)

Clinical Characteristics, Health Care Resource Utilization and Direct Medical Costs of Rotavirus Hospitalizations in Spain (2013-2018)

Contact Info

Product

Resources

About